SR-9009 Powder (Stenabolic) | 2 Grams

SR-9009 (Stenabolic) Powder — 2 Grams

SR-9009, also designated SR9009 or stenabolic, is a synthetic agonist of the REV-ERBα and REV-ERBβ nuclear receptors, components of the molecular circadian clock. Although it is often catalogued alongside SARMs, it is mechanistically distinct and does not bind the androgen receptor. This listing is a research-grade reference compound supplied in powder form for in vitro and laboratory investigation. Identity and purity are third-party verified and documented by a downloadable Certificate of Analysis.

• 99.68% purity (HPLC)
• Third-party verified
• 2,050 mg net
• Public COA
• UV-resistant foil pouch

Specifications & Documentation

Specifications Lab Reports Storage & Handling

Compound

SR-9009 (SR9009 / Stenabolic)

IUPAC Name

ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate

CAS Number

1379686-30-2Copy

Molecular Formula

C₂₀H₂₄ClN₃O₄SCopy

Molar Mass

437.94 g/mol

Compound Class

REV-ERBα/β agonist · Non-steroidal

WADA Classification

Prohibited — Class S4 (Hormone and Metabolic Modulators)

Form

Crystalline powder

Net Quantity

2,050 mg per pouch

Verified Purity

99.68% by HPLC (current COA)

Quality & Analytical Transparency

Independent analysis has repeatedly found that research compounds sold online are frequently mislabeled or adulterated. A 2017 JAMA investigation that chemically analyzed products marketed as SARMs, a category that commonly includes SR-9009, found that only a minority accurately matched their labeled contents, and a substantial share contained unapproved or entirely different substances.^[5] Third-party testing is the control that distinguishes a documented reference compound from an unverified one.

Research Context

SR-9009 was developed at The Scripps Research Institute and first described in 2012 as a synthetic ligand for the REV-ERB nuclear receptors, which regulate circadian gene expression and metabolic pathways. The original report characterized its effects on circadian behavior and on gene expression in liver, skeletal muscle, and adipose tissue in mice,^[1] and follow-up work examined REV-ERBα’s role in skeletal muscle mitochondrial biogenesis and oxidative capacity.^[2] It has also been used as a tool compound in cancer cell and oncogene-induced senescence models.^[3] Importantly for experimental design, later research found that SR-9009 affects cell proliferation and metabolism even in cells lacking both REV-ERB receptors, indicating off-target activity that complicates attributing its effects to REV-ERB alone.^[4]

This material is supplied strictly as a reference compound to support such laboratory investigation. It is not a therapeutic product, dietary supplement, or sports supplement, and no clinical or performance outcomes are claimed or implied for any individual.

Scientific References

1. Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62–68.
2. Woldt E, Sebti Y, Solt LA, et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med. 2013;19(8):1039–1046.
3. Sulli G, Rommel A, Wang X, et al. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018;553(7688):351–355.
4. Dierickx P, Emmett MJ, Jiang C, et al. SR9009 has REV-ERB–independent effects on cell proliferation and metabolism. Proc Natl Acad Sci USA. 2019;116(25):12147–12152.
5. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004–2010.
6. World Anti-Doping Agency. The Prohibited List, Section S4: Hormone and Metabolic Modulators. WADA.org.

Research Disclaimer